Neurobiological Background for the Development of New Drugs in Schizophrenia
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurobiological Background for the Development of New Drugs in Schizophrenia
Authors
Keywords
-
Journal
CLINICAL NEUROPHARMACOLOGY
Volume 34, Issue 3, Pages 111-126
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2011-05-17
DOI
10.1097/wnf.0b013e318215c2f7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice
- (2009) Francisco López-Muñoz et al. BRAIN RESEARCH BULLETIN
- Group II metabotropic glutamate receptors and schizophrenia
- (2009) José L. Moreno et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia
- (2009) Esther Garcia et al. CNS DRUGS
- Antipsychotics in the early stage of development
- (2009) Falko Biedermann et al. CURRENT OPINION IN PSYCHIATRY
- Iloperidone: a new option for the treatment of schizophrenia
- (2009) Andrew J Cutler Expert Review of Neurotherapeutics
- Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic
- (2009) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia
- (2009) Glenn Schwarcz et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
- (2008) Robert Freedman et al. AMERICAN JOURNAL OF PSYCHIATRY
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
- Estrogen in Severe Mental Illness
- (2008) Jayashri Kulkarni et al. ARCHIVES OF GENERAL PSYCHIATRY
- Upcoming Agents for the Treatment of Schizophrenia
- (2008) Delia Bishara et al. DRUGS
- Emerging drugs for schizophrenia
- (2008) Ofer Agid et al. EXPERT OPINION ON EMERGING DRUGS
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
- (2008) Atheir Abbas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
- (2008) M. Shahid et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia
- (2008) Dennis H. Kim et al. Neurotherapeutics
- Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
- (2008) J. A. Lieberman et al. PHARMACOLOGICAL REVIEWS
- Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
- (2008) Daniel E. Casey et al. PSYCHOPHARMACOLOGY
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia
- (2008) P. Jeffrey Conn et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
- (2007) Hsien-Yuan Lane et al. BIOLOGICAL PSYCHIATRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started